Agenus Inc AGEN Fundamentals and Key Ratios

Agenus Inc. (AGEN) Fundamentals


Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

SHARE INFORMATION
Market Cap	$ 801,654,732
Shares Outstanding	304,811,685
Float	289,438,631
Percent Float	94.96%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 295,664,000
Latest Fiscal EPS	$ -0.21
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	331
Institutional Holdings Date	2022-10-31
Institutional Bought Previous 3 Months	20,886,468
Institutional Holdings Percent	80.3%
Institutional Sold Previous 3 Months	19,913,544
Insider Holdings Date	2022-10-31
Insider Bought Previous 3 Months	34,397
Insider Holdings Percent	2.8
Insider Sold Previous 3 Months	-
Insider Shares Owned	7,975,641

TRADING INFO
52 Week High	$ 3.62
52 Week Low	$ 1.25
52 Week High Change	$ -16.51
21 Day Moving Average	$ 2.699
21 Day Extended Moving Average	$ 2.757
50 Day Moving Average	$ 2.5388
50 Day Extended Moving Average	$ 2.6395
200 Day Moving Average	$ 2.3953
200 Day Extended Moving Average	$ 2.6673
10 Day Average Volume	4,524,909
20 Day Average Volume	5,315,080
30 Day Average Volume	4,870,116
50 Day Average Volume	4,958,979
Alpha	0.006440
Beta	1.3021
Standard Deviation	0.226460
R2	0.092685
7 Day Price Change	$ -0.41
7 Day Percent Change	-13.49%
21 Day Price Change	$ 0.40
21 Day Percent Change	17.94%
30 Day Price Change	$ 0.08
30 Day Percent Change	3.14%
Month to Date Price Change	$ 0.12
Month to Date Percent Change	4.78%
Quarter to Date Price Change	$ 0.58
Quarter to Date Percent Change	28.29%
180 Day Price Change	$ 1.02
180 Day Percent Change	63.35%
200 Day Price Change	$ 1.00
200 Day Percent Change	61.35%
Year to Date Price Change	$ -0.59
Year to Date Percent Change	-18.32%

Agenus Inc. (AGEN) Key Ratios

PROFITABILITY
EBIT Margin	-181.4%
EBITDA Margin	-173.9%
Pre-Tax Profit Margin	-267.5%
Profit Margin Count	0.57%
Gross Margin	-303.1%
Profit Margin TOT	0.57%

INCOME STATEMENTS
Revenue	$ 89,900,000
Revenue Per Share	$ 0.2949
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	-16.00
Total Debt To Equity	23.50
Int Coverage	-2.70
Current Ratio	1.50
Leverage Ratio	62.40
Quick Ratio	1.30
Long Term Debt To Capital	0.95

VALUATION MEASURES
PE Ratio	-3.20
Enterprise Value	$ 677,838,315
Price to Sales	8.9172
Price to Free Cash	-4.00
PE High Last 5 Years	-3.10
Price To Book	218.60
Price To Cash Flow	50.00
PE Low Last 5 Years	-2.40
Price to Tangible Book	-16.00

MANAGEMENT EFFECTIVENESS
Receivables Turnover	17.80
Invoice Turnover	0.00
Assets Turnover	0.30
Return Assets	-56.13
Return on Equity	-2,978.48
Return on Capital	-210.43

Agenus Inc. (AGEN) Profile

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	KPMG LLP
CEO	Garo H. Armen
Emplyoees	441
Last Audit	UQ
CIK	0001098972
Industry	Biotechnology
Sector	Healthcare
NAICS	Biological Product (except Diagnostic) Manufacturing(325414)

CONTACT INFO
Address	3 Forbes Road Lexington, MA 02421-7305
Website	https://www.agenusbio.com
Facsimile	+1 781 674-4200
Telephone	+1 781 674-4400
Email	investor@agenusbio.com

Quotes:

IHub: